Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U S Department of Defense s Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD) kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans.
SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the.
- Acadia Healthcare is the Largest Stand-Alone Behavioral Health Company in the United States Operating a Network of Nearly 240 Behavioral Health Facilities in 39 States and Puerto Rico
NEW YORK,. | September 13, 2022